Orphai Therapeutics’ Phase 2a LAM-001 Study Selected for Oral Presentation at the American Thoracic Society (ATS) 2026 International ConferenceNEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Orphai Therapeutics Inc. (“Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with diseases of significant unmet need, today announced that results from its Phase 2a study of LAM-001 in pulmonary hypertension have been slated for oral presentation at the American Thoracic Society (ATS) 2026 International Conference taking place May 15 – 20, 2026 in Orlando, FL.
OrphAI Therapeutics receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European UnionGUILFORD, Conn., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today that it has received Orphan Drug Designation (ODD) in the European Union (EU) for the treatment of amyotrophic lateral sclerosis (ALS). AIT-101 previously received ODD from the U.S. FDA in June 2023 for the treatment of ALS.
OrphAI Therapeutics Announces Oral Presentation and Posters at the 22nd Annual NEALS ConferenceGUILFORD, Conn., Oct. 02, 2023 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today data presentations at the 22nd Annual NEALS (Northeast ALS Consortium) meeting being held October 4 - 6, 2023 in Clearwater Florida.
